000120132 001__ 120132
000120132 005__ 20240228135013.0
000120132 0247_ $$2doi$$a10.1158/1078-0432.CCR-14-1692
000120132 0247_ $$2pmid$$apmid:25294899
000120132 0247_ $$2ISSN$$a1078-0432
000120132 0247_ $$2ISSN$$a1557-3265
000120132 0247_ $$2altmetric$$aaltmetric:2754033
000120132 037__ $$aDKFZ-2017-00715
000120132 041__ $$aeng
000120132 082__ $$a610
000120132 1001_ $$aPianko, Matthew J$$b0
000120132 245__ $$aWhole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease.
000120132 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2014
000120132 3367_ $$2DRIVER$$aarticle
000120132 3367_ $$2DataCite$$aOutput Types/Journal article
000120132 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1490878690_7655
000120132 3367_ $$2BibTeX$$aARTICLE
000120132 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120132 3367_ $$00$$2EndNote$$aJournal Article
000120132 520__ $$aDetection of lytic bone lesions is crucial in the workup for multiple myeloma and very often dictates the decision to start treatment. Conventional radiography, despite decades of use, is often insufficient for detection of bone disease in multiple myeloma. Modern imaging techniques such as MRI, PET, and CT offer superior detection of myeloma bone disease and extramedullary manifestations of plasma cell dyscrasias. Novel whole-body low-dose computed tomography (WBLDCT) protocols allow for collection of superior image detail of the skeleton at doses of radiation similar to those used for conventional planar radiography. Several studies have shown that WBLDCT has a superior detection rate for lytic bone lesions compared with whole-body X-ray (WBXR), potentially leading to restaging and changes in therapy. MRI and PET provide imaging data important for assessing disease activity and prognostication. Because of several advantages over WBXR, WBLDCT is already the standard imaging technique for use in patients with multiple myeloma in many European institutions. However, the radiographic skeletal survey or WBXR is still the initial study of choice used to screen for myeloma bone disease in many institutions. In this review, we aim to explore the changing landscape of imaging for myeloma bone disease through use of modern imaging techniques.
000120132 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000120132 588__ $$aDataset connected to CrossRef, PubMed,
000120132 7001_ $$aTerpos, Evangelos$$b1
000120132 7001_ $$aRoodman, G David$$b2
000120132 7001_ $$aDivgi, Chaitanya R$$b3
000120132 7001_ $$aZweegman, Sonja$$b4
000120132 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b5$$udkfz
000120132 7001_ $$aLentzsch, Suzanne$$b6
000120132 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-14-1692$$gVol. 20, no. 23, p. 5888 - 5897$$n23$$p5888 - 5897$$tClinical cancer research$$v20$$x1557-3265$$y2014
000120132 909CO $$ooai:inrepo02.dkfz.de:120132$$pVDB
000120132 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000120132 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000120132 9141_ $$y2014
000120132 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2015
000120132 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120132 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120132 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120132 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120132 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120132 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120132 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120132 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120132 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120132 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CANCER RES : 2015
000120132 9201_ $$0I:(DE-He78)E013-20160331$$kE013$$lHämatoonkologische Bildgebung$$x0
000120132 980__ $$ajournal
000120132 980__ $$aVDB
000120132 980__ $$aI:(DE-He78)E013-20160331
000120132 980__ $$aUNRESTRICTED